Related Experiment Video
Updated: Mar 9, 2026
08:15
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
1.0K
New therapeutic agents in diabetic nephropathy
1Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
The Korean Journal of Internal Medicine
|January 4, 2017
Summary
New diabetic nephropathy (DN) therapies target intrinsic renal pathways, offering hope beyond glucose control. These treatments may also improve cardiovascular health and manage obesity in diabetic patients.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic nephropathy (DN) research often focuses on molecular mechanisms, yet effective treatments beyond glucose control are limited.
- Current therapies for DN, primarily renin-angiotensin-aldosterone system inhibitors, are suboptimal and do not fully address disease complexity.
- The heterogeneity of DN and unclear renal endpoints hinder the evaluation of new drug efficacy.
Purpose of the Study:
- To review novel therapeutic agents for diabetic nephropathy (DN).
- To discuss treatments targeting intrinsic renal pathways, including anti-inflammatory, antifibrotic, and metabolic mechanisms.
- To explore the potential systemic benefits of these agents for comorbid conditions associated with diabetes.
Main Methods:
- Literature review of current research on diabetic nephropathy (DN) therapeutics.
- Analysis of studies focusing on intracellular signaling pathways in renal cells.
- Evaluation of evidence for novel agents' efficacy in preclinical and clinical settings.
Main Results:
- Emerging therapies target intrinsic renal pathways, showing promise for DN management.
- Novel agents demonstrate favorable metabolic effects on renal aspects of DN.
- These treatments may offer systemic benefits, addressing obesity and cardiovascular disease risk in diabetic patients.
Conclusions:
- There is a significant unmet need for effective diabetic nephropathy (DN) treatments beyond glucose regulation.
- Novel therapeutic strategies focusing on intrinsic renal pathways offer promising avenues for DN management.
- These agents have the potential to improve renal outcomes and address systemic comorbidities in patients with diabetes.
Keywords:
AMP-activated protein kinasesDiabetic nephropathiesIncretinsSodium/glucose co-transporter 2More Related Videos
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
791
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
2.0K
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
771
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
771
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
785
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
785
01:16Antihypertensive Drugs: Action of Diuretics
2.6K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.6K
01:15Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K